MarketPulse

randomized controlled trial

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Organogenesis Wins Key Trial for Diabetic Ulcer Treatment, Bolstering PuraPly®AM Case

Organogenesis's PuraPly®AM met primary endpoint in diabetic ulcer trial with statistically significant 12-week wound closure, supporting future insurance coverage expansion.
ORGOregenerative medicinerandomized controlled trial
GlobeNewswire Inc.GlobeNewswire Inc.··Actg

Tecovirimat Shows No Clinical Benefit Over Placebo in Mpox Trial

Tecovirimat showed no clinical benefit over placebo in treating mpox, with 79% vs 81% achieving resolution by day 29 in a major trial.
SIGAclinical trialtecovirimat